Compound ID | 2875
RG6319, GDC-5780
Class: Small molecule antibacterial agent
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | LepB inhibitor (arylomycin) |
| Target Pathogen: | Active against Escherichia coli |
| Description: | For complicated urinary tract infections |
| Institute where first reported: | Genentech; Roche |
| Year first mentioned: | 2022 |
| Highest developmental phase: | Phase 1 (ISRCTN16073754) |
| Development status: | Active as of 2024 |
| External links: | |
| Citation: | https://www.nature.com/articles/s41429-023-00629-8 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.